Overview

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment nave), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (BNT327) in combination with chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

BioNTech SE

Collaborators:

BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Bristol-Myers Squibb

Treatments:

130-nm albumin-bound paclitaxel
Gemcitabine